Webcast Alert: Isis Pharmaceuticals Hosts Expert Panel Conference Call to Discuss Mipomersen Data Presented at the ESC Congress 2010
CARLSBAD, Calif., Aug. 30 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. announces the following
Data from mipomersen Phase 3 trial in heFH patients presented at What: ESC When: Wednesday, September 1, 2010 at 4:00 p.m. ET / 1:00 p.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our Web site listed above.
If you are unable to participate during the live event, a replay
of the webcast will be available for a limited time at
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop
novel drugs for its product pipeline and for its partners. The
Company has successfully commercialized the world's first antisense
drug and has 23 drugs in development. Isis' drug development
programs are focused on treating cardiovascular, metabolic, and
severe neurodegenerative diseases and cancer. Isis' partners are
developing antisense drugs invented by Isis to treat a wide variety
of diseases. Isis and Alnylam Pharmaceuticals are joint owners of
Regulus Therapeutics Inc., a company focused on the discovery,
development and commercialization of microRNA therapeutics. Isis
also has made significant innovations beyond human therapeutics
resulting in products that other companies, including Abbott, are
commercializing. As an innovator in RNA-based drug discovery and
development, Isis is the owner or exclusive licensee of over 1,600
issued patents worldwide. Additional information about Isis is
available at www.isispharm.com.
Source: Isis Pharmaceuticals, Inc.
CONTACT: Kristina Lemonidis, Director, Investor Relations,
+1-760-603-2490; or Amy Blackley, Ph.D., Assistant Director, Corporate
Communications, +1-760-603-2772, both of Isis Pharmaceuticals, Inc.
Posted: August 2010